CompletedPhase 1NCT01742221
Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure
Studying Acute radiation syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neumedicines Inc.
- Principal Investigator
- Nicholas Siebers, MD, OTCovance Clinical Research Unit
- Intervention
- HemaMax(biological)
- Enrollment
- 60 enrolled
- Eligibility
- 18-45 years · All sexes
- Timeline
- 2012 – 2012
Study locations (1)
- Covance Clinical Research Unit, Madison, Wisconsin, United States
Collaborators
Department of Health and Human Services
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01742221 on ClinicalTrials.govOther trials for Acute radiation syndrome
Additional recruiting or active studies for the same condition.